Protective effect of vitamin B therapy on bone and cardiovascular disease

Recent Patents on Cardiovascular Drug Discovery

Volumn 4, Issue 1, 2009, Pages 37-44

  Righetti, Marco ^a  

^a DESIO HOSPITAL   (Italy)

Author keywords

Bone and cardiovascular disease and metabolism disorders; Folic acid; Homocysteine; Homocystinuria; Hyperhomocysteinemia; Vitamin B

Indexed keywords

ALBUMIN; BENZODIAZEPINE DERIVATIVE; FOLIC ACID; FOLINIC ACID; HOMOCYSTEINE; METHIONINE; THIAMINE; VITAMIN B GROUP; VITAMIN B COMPLEX;

BONE DISEASE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIET THERAPY; HEART PROTECTION; HEMODIALYSIS; HIP FRACTURE; HOMOCYSTINURIA; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; LOW DRUG DOSE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; STROKE; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION; CHRONIC KIDNEY FAILURE; DRUG EFFECT;

BONE DISEASES; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; VITAMIN B COMPLEX;

EID: 65549123065     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489009787260061     Document Type: Review

References (70)

1. Roe DA, Lucy W. A biographical sketch. J Nutr 1978; 108(9): 1379-1383.
2. From "Nobel Lectures", Chemistry 1942-1962. Amsterdam, Elsevier Publishing Company 1964.
3. Carson NAJ, Neill DW. Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland. Arch Dis Child 1962; 37: 505-513.
4. McCully KS. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111-128.
5. Angier RB, Boothe JH, Hutchings BL, et al. Synthesis of a compound identical with the L. casei factor isolated from liver. Science 1945; 102: 227-228.
6. Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1990; 1: 228-237.
7. Homocysteine Lowering Trialists Collaboration. Lowering blood homocysteine with folic acid based supplements: Meta-analyses of randomised trials. BMJ 1998; 316: 894-898.
8. Righetti M, Ferrario GM, Milani S, et al. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. Med Sci Monit 2003; 9: PI 19-24.
9. Ducloux D, Aboubakr A, Motte G, et al. Hyperhomocysteinemia therapy in hemodialysis patients: Folinic versus folic acid in combination with vitamin B6 and B12. Nephrol Dial Transplant 2002; 17: 865-870.
10. Righetti M, Tommasi A, Lagona C, La Rosa L, Uccellini M, Sessa A. Effective homocysteine-lowering vitamin B treatment in peritoneal dialysis patients. Perit Dial Int 2004; 24: 373-377.
11. Mudd SH, Levy HL, Skovby F, et al. Eds. In: Methionine transamination (Disorders of transsulfuration). The metabolic and molecular bases of inherited disease, 7th Ed. NY, McGraw-Hill, Inc 1995: 1283-1284.
12. Tangerman A, Wilcken B, Levy HL, Boers GH, Mudd SH. Methionine transamination in patients with homocystinuria due to cystathionine beta-synthase deficiency. Metabol Clin Exp 2000; 49: 1071-1077.
13. Franken DG, Blom HJ, Boers GH, Tangerman A, Thomas CM, Trijbels FJ. Thiamine supplementation does not reduce fasting blood homocysteine concentration in most homozygotes for homocystinuria. Biochim Biophys Acta 1996; 1317: 101-104.
14. Skoupy S, Födinger M, Veitl M, et al. Riboflavin is a determinant of total homocysteine plasma concentrations in end-stage renal disease patients. J Am Soc Nephrol 2002; 13: 1331-1337.
15. Schupp N, Schmid U, Heidland A, Stopper H. New approaches for the treatment of genomic damage in end-stage renal disease. J Ren Nutr 2008; 18: 127-133.
16. Beerenhout C, Luik Aj, Jeuken-Mertens SGJ, et al. Pre-dilution online haemofiltration vs. low-flux haemodialysis: A randomized prospective study. Nephrol Dial Transplant 2005; 20: 1155-1163.
17. Righetti M, Ferrario GM, Serbelloni P, Milani S, Tommasi A. Homocysteine reduction rate in internal haemodiafiltration: A comparison with other mixed dialysis therapies. Nephrol Dial Transplant 2006; 21: 2034-2035.
18. De Vriese AS, Langlois M, Bernard D, et al. Effect of dialyser membrane pore size on plasma homocysteine levels in haemodialysis patients. Nephrol Dial Transplant 2003; 18: 2596-2600.
19. Friedman AN, Bostom AG, Levy AS, Rosenberg IH, Selhub J, Pierratos A. Plasma total homocysteine levels among patients undergoing nocturnal vs standard hemodialysis. J Am Soc Nephrol 2002; 13: 265-268.
20. Sholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation 2004; 109: 369-374.
21. Perna AF, Ingrosso D, Lombardi C, et al. Possibile mechanisms of homocysteine toxicity. Kidney Int 2003; 63: S137-S140.
22. Hubmacher D, Tiedemann K, Bartels R, et al. Modification of the structure and function of fibrillin-1 by homocysteine suggests a potential pathogenetic mechanism in homocystinuria. J Biol Chem 2005; 280: 34946-34955.
23. Ingrosso D, Cimmino A, Perna AF, et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinemia in patients with uremia. Lancet 2003; 361: 1693-1699.
24. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356: 147-152.
25. Eknoyan G, Lameire N, Barsoum R, et al. The burden of kidney disease: Improving global outcomes. Kidney Int 2004; 66: 1310-1314.
26. Rayner HC, Pisoni RL, Bommer J, et al. Mortality and hospitalization in haemodialysis patients in five European countries: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 108-120.
27. Conte F, Salomone M. Italian Registry of Dialysis and Transplantation, Report 2001. Available from: http://www.sinridt.org/sin-ridt/ sin-ridt.org.htm
28. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The european concerted action project. J Am Med Assoc 1997; 277: 1775-1781.
29. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. Br Med J 2002; 325: 1202-1208.
30. Fissell RB, Bragg-Gresham JL, Gillespie BW, et al. International variation in vitamin prescription and association with mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 293-299.
31. Righetti M, Serbelloni P, Milani S, Ferrario GM. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif 2006; 24: 379-386.
32. Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol 2004; 15: 442-453.
33. Wrone EM, Hornberger JM, Zehnder JL, Mccann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004; 15: 420-426.
34. Ducloux D, Klein A, Kazory A, Devillard N, Chalopin JM. Impact of malnutrition-inflammation on the association between homocysteine and mortality. Kidney Int 2006; 69: 331-335.
35. Suliman M, Stenvinkel P, Qureshi AR, et al. The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. Nephrol Dial Transplant 2007; 22: 209-217.
36. Jamison RL, Hartigan P, Kaufman JS, et al. Veterans Affair Site Investigators. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: A randomized controlled trial. JAMA 2007; 298: 1163-1170.
37. Baber U, de Lemos JA, Khera A, et al. Non traditional risk factors predict coronary calcification in chronic kidney disease in a population-based cohort. Kidney Int 2008; 73: 615-621.
38. Mann JFE, Sheridan P, McQueen MJ, et al. On behalf of the HOPE-2 investigators. Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease-results of the renal Hope-2 study. Nephrol Dial Transplant 2008; 23: 645-653.
39. Righetti M. Hopeful for a second HOPE-2 post-hoc analysis. Nephrol Dial Transplant 2008; 23: 2428-2429.
40. Mann JFE, Lonn EM. Reply to Hopeful for a second HOPE-2 posthoc analysis. Nephrol Dial Transplant 2008; 23: 2429-2430.
41. Yap S, Boers GHJ, Wilcken B, et al. Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: A multicenter observational study. Arterioscler Thromb Vasc Biol 2001; 21: 2080-2085.
42. Yang Q, Botto LD, Erickson JD, et al. Improvement in stroke mortality in Canada and the United States: 1990 to 2002. Circulation 2006; 13: 1335-1343.
43. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565-575.
44. Spence JD, Bang H, Chambless LE, Stampfer MJ. Vitamin intervention for stroke prevention trial. An efficacy analysis. Stroke 2005; 36: 2404-2409.
45. Bønaa KH, Njølstad I, Ueland PM, et al. NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354: 1578-1588.
46. Lonn E, Yusuf S, Arnold MJ, et al. Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-1577.
47. Bazzano LA, Reynolds K, Holder KN, He Y. Effect of folic acid supplementation on risk of cardiovascular diseases. JAMA 2006; 296: 2720-2726.
48. Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention: A meta-analysis. Lancet 2007; 369: 1876-1882.
49. Albert CM, Cook NR, Gaziano JM, et al. Effects of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: A randomized trial. JAMA 2008; 299: 2027-2036.
50. Ebbing M, Bleie ø, Ueland PM, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography. JAMA 2008; 300(7): 795-804.
51. Potena L, Grigioni F, Masetti M, et al. Long-term effect of folic acid therapy in heart transplant recipients: Follow-up analysis of a randomized study. Transplantation 2008; 85: 1146-1150.
52. Stopper H, Treutlein AT, Bahner U, et al. Reduction of the genomic damage level in haemodialysis patients by folic acid and vitamin B12 supplementation. Nephrol Dial Transplant 2008; 23: 3272-3279.
53. Zoungas S, McGrath BP, Branley P, et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure. JACC 2006; 47: 1108-1116.
54. Mark SD, Wang W, Fraumeni JF Jr., et al. Lowered risks of hypertension and cerebrovascular disease after vitamin/mineral supplementation: The Linxian Nutrition Intervention. Am J Epidemiol 1996, 143: 658-664.
55. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, van Veldhuisen DJ. Secondary prevention with folic acid: Results of the Goes extension study. Heart 2005; 91: 1213-1214.
56. Lubec B, Fang-Kircher S, Lubec T, Blom HJ, Boers GHJ. Molecular basis of disease: Evidence for McKusick's hypothesis of deficient collagen cross-linking in patients with homocystinuria. Biochim Biophys Acta 1996; 1315: 159-162.
57. Herrmann M, Tami A, Wildemann B, et al. Hyperhomocysteinemia induces a tissue specific accumulation of homocysteine in bone by collagen binding and adversely affects bone. Bone 2008. Epub ahead of print.
58. McLean RR, Jacques PF, Selhub J, et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004; 350: 2042-2049.
59. Van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004; 350: 2033-2041.
60. Gjesdal CG, Vollset SE, Ueland PM, Refsum H, Meyer HE, Tell GS. Plasma homocysteine, folate, vitamin B12 and the risk of hip fractures: The Hordaland homocysteine study. J Bone Miner Res 2007; 22: 747-756.
61. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K. Effect of folate and mecobalamin on hip fractures in patients with stroke: A randomized controlled trial. JAMA 2005; 293: 1082-1088.
62. Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006; 70(7): 1358-1366.
63. Righetti M, Ferrario G, Serbelloni P, Milani S, Dossi C, Tommasi A. High bone and cardiovascular morbidity in folate-resistant hemodialysis patients. Nephrol Dial Transplant Plus 2008; 1 (S2): ii211 (MO002) (oral presentation to the ERA-EDTA Congress, Stockholm 2008).
64. Yusuf, S., Hirsh, J., Eikelboom, J.: EP1895299 (2008).
65. Tabibiazar, R., Hytopoulos, E.: WO2008080126 (2008).
66. Johnson, R.J., Henderson, G., Angerhofer, A.: WO2008002911A2 (2008).
67. Levy, A.: US20080044399A1 (2008).
68. Sethi, R., Haque, W.: EP1872797A2 (2008).
69. Austin, R.C., Werstuck, G.: US20080039382A1 (2008).
70. Herrmann M, Schmidt JP, Umansakaya N, et al. The role of hyperhomocysteinemia as well as folate, vitamin B6 and B12 deficiencies in osteoporosis: A systematic review. Clin Chem Lab Med 2007; 45: 1621-1632.